A paediatric vaccination vector based on live attenuated measles vaccine

Therapie

Volumn 60, Issue 3, 2005, Pages 227-233

  Lorin, Clarisse ^a   Combredet, Chantal ^a   Labrousse, Valérie ^a   Mollet, Lucile ^a   Desprès, Philippe ^a   Tangy, Frédéric ^a  

^a INSTITUT PASTEUR   (France)

Author keywords

HIV; Measles; Recombinant live attenuated vaccine; West Nile virus

Indexed keywords

ATTENUAVAX; MEASLES VACCINE; LIVE VACCINE; RECOMBINANT VACCINE; VIRUS ENVELOPE PROTEIN;

CONFERENCE PAPER; DEVELOPING COUNTRY; DRUG COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE RESPONSE; IMMUNITY; MEASLES; MEASLES VACCINATION; PATHOGENESIS; PATHOGENICITY; PRIORITY JOURNAL; PROTECTION; PROTEIN EXPRESSION; PROVOCATION TEST; WEST NILE FLAVIVIRUS; CHILD; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; MOLECULAR CLONING; REVIEW; VIROLOGY;

CHILD; CLONING, MOLECULAR; HIV-1; HUMANS; MEASLES; MEASLES VACCINE; VACCINES, ATTENUATED; VACCINES, SYNTHETIC; VIRAL ENVELOPE PROTEINS;

EID: 24944466497     PISSN: 00405957     EISSN: 00405957     Source Type: Journal    
DOI: 10.2515/therapie:2005029     Document Type: Conference Paper

References (53)

1. Centers for Disease Control and Prevention. Ten great public health achievements: United States, 1990-1999. MMWR Morbid Mort Wkly Rep 1999; 48: 241-3
2. Enders JF, Peebles TC. Propagation in tissue cultures of cytopathogenic agents from patients with measles. Proc Soc Exp Biol Med 1954; 86: 277-86
3. Griffin D. Measles virus. In: Knipe D, Howley P, editors. Field's virology. 4th ed. Vol. 2. Philadelphia (PA): Lippincott-Raven Publishers, 2001: 1401-41
4. Hilleman M. Current overview of the pathogenesis and prophylaxis of measles with focus on practical implications. Vaccine 2002; 20: 651-65
5. Schwarz A. Preliminary tests of a highly attenuated measles vaccine. Am J Dis Child 1962; 103: 216-9
6. Parks CL, Lerch RA, Walpita P, et al. Comparison of predicted amino acid sequences of measles virus strains in the Edmonston vaccine lineage. J Virol 2001; 75: 910-20
7. Parks CL, Lerch RA, Walpita P, et al. Analysis of the noncoding regions of measles virus strains in the Edmonston vaccine lineage. J Virol 2001; 75: 921-33
8. Ovsyannikova IG, Dhiman N, Jacobson RM, et al. Frequency of measles virus-specific CD4+ and CD8+ T cells in subjects seronegative or highly seropositive for measles vaccine. Clin Diagn Lab Immunol 2003; 10: 411-6
9. Radecke F, Spielhofer P, Schneider H, et al. Rescue of measles viruses from cloned DNA. EMBO J 1995; 14: 5773-84
10. Radecke F, Billeter M. Reverse genetics meets the nonsegmented negative-strand RNA viruses. Rev Med Virol 1997; 7: 49-63
11. Spielhofer P, Bachi T, Fehr T, et al. Chimeric measles viruses with a foreign envelope. J Virol 1998; 72: 2150-9
12. Singh M, Billeter M. A recombinant measles virus expressing biologically active human interleukin-12. J Gen Virol 1999; 80: 101-6
13. Singh M, Cattaneo R, Billeter MA. A recombinant measles virus expressing hepatitis B virus surface antigen induces humoral immune responses in genetically modified mice. J Virol 1999; 73: 4823-8
14. Wang Z, Hangartner T, Cornu L, et al. Recombinant measles viruses expressing heterologous antigens of mumps and simian immunodeficiency viruses. Vaccine 2001; 19: 2329-36
15. Lorin C, Mollet L, Delebecque F, et al. A single injection of recombinant measles vaccines expressing HIV-1 clade B envelope glycoproteins induces neutralizing antibodies and cellular immune responses to HIV. J Virol 2004; 78: 146-57
16. Combredet C, Labrousse-Najburg V, Mollet L, et al. A molecularly cloned Schwarz strain of measles virus vaccine induces strong immune responses in macaques and transgenic mice. J Virol 2003; 77: 11546-54
17. Buynak E, Weibel R, Whitman Jr JE, et al. Combined live measles, mumps, and rubella virus vaccines. JAMA 1969; 207: 2259-62
18. Parks CL, Lerch RA, Walpita P, et al. Enhanced measles virus cDNA rescue and gene expression after heat shock. J Virol 1999; 73: 3560-6
19. Calain P, Roux L. The rule of six, a basic feature for efficient replication of Sendai virus defective interfering RNA. J Virol 1993; 67: 4822-30
20. Van Binnendijk RS, van der Heijden RWJ, van Amerongen G, et al. Viral replication and development of specific immunity in macaques after infection with different measles virus strains. J Infect Dis 1994; 170: 443-8
21. Kobune F, Takahashi H, Terao K, et al. Nonhuman primate models of measles. Lab Anim Sci 1996; 46: 315-20
22. 2004 report on the global AIDS epidemic. Joint United Nations Programme on HIV/AIDS (UNAIDS), July 2004 [online]. Available from URL: http://www.unaids.org/bangkok2004/GAR2004_html/GAR2004_00_en.htm
23. Barnett SW, Lu S, Srivastava I, et al. The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region. J Virol 2001; 75: 5526-40
24. Jeffs S, Shotton C, Balfe P, et al. Truncated gp 120 envelope glycoprotein of human immunodeficiency virus 1 elicits broadly reactive neutralizing immune response. J Gen Virol 2002; 83: 2723-32
25. Binley JM, Sanders RW, Clas B, et al. A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure. J Virol 2000; 74: 627-43
26. Srivastava I, VanDorsten K, Vojtech L, et al. Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable region. J Virol 2003; 77: 2310-20
27. Lu S, Wyatt R, Richmond JF, et al. Immunogenicity of DNA vaccines expressing human immunodeficiency virus type 1 envelope glycoprotein with and without deletions in the V1/2 and V3 regions. AIDS Res Hum Retroviruses 1998; 14: 151-5
28. Kim Y, Han D, Cao C, et al. Immunogenicity and ability of variable loop-deleted human immunodeficiency virus type 1 envelope glycoproteins to elicit neutralizing antibodies. Virology 2003; 305: 124-37
29. Moore JP, Parren PW, Burton DR. Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development. J Virol 2001; 75: 5721-9
30. Casimiro DR, Chen L, Fu TM, et al. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J Virol 2003; 77: 6305-13
31. Earl PL, Wyatt LS, Montefiori DC, et al. Comparison of vaccine strategies using recombinant env-gag-pol MVA with or without an oligomeric Env protein boost in the SHIV rhesus macaque model. Virology 2002; 294: 270-81
32. Dilraj A, Cutts FT, de Castro JF, et al. Response to different measles vaccine strains given by aerosol and subcutaneous routes to schoolchildren: a randomized trial. Lancet 2000; 355: 798-803
33. Dilraj A, Cutts F, Bennett J, et al. Persistence of measles antibody two years after revaccination by aerosol or subcutaneous routes. Pediatr Infect Dis J 2000; 19: 1211-3
34. Sepulveda-Amor J, Valdespino-Gomez JL, Garcia-Garcia ML, et al. A randomized trial demonstrating successful boosting responses following simultaneous aerosols of measles and rubella (MR) vaccines in school age children. Vaccine 2002; 20: 2790-5
35. Gans H, Yasukawa L, Rinki M, et al. Immune responses to measles and mumps vaccination of infants at 6, 9 and 12 months. J Infect Dis 2001; 184: 817-26
36. Gans H, DeHovitz R, Forghani B, et al. Measles and mumps vaccination as a model to investigate the developing immune system: passive and active immunity during the first year of life. Vaccine 2003; 21: 3398-405
37. Siegrist CA. Mechanisms by which maternal antibodies influence infant vaccine responses: review of hypotheses and definition of main determinants. Vaccine 2003; 21: 3406-12
38. Esolen LM, Ward BJ, Moench TR, et al. Infection of monocytes during measles. J Infect Dis 1993; 168: 47-52
39. Hilleman MR. Vaccinology, immunology, and comparative pathogenesis of measles in the quest for a preventive against AIDS. AIDS Res Hum Retroviruses 1994; 10: 3-12
40. Matzinger P. The danger model: a renewed sense of self. Science 2002; 296: 301-5
41. Despres P, Combredet C, Frenkiel M, et al. Live measles vaccine expressing the secreted form of the West Nile virus envelope glycoprotein protects against West Nile virus encephalitis. J Infect Dis 2005; 191 (2): 207-14
42. Brinton MA. The molecular biology of West Nile virus: a new invader of the Western Hemisphere. Annu Rev Microbiol 2002; 56: 371-402
43. Petersen LR, Marfin AA, Gubler DJ. West Nile virus. JAMA 2003; 290: 524-8
44. Lanciotti R, Ebel G, Deubel V, et al. Complete genome sequences and phylogenetic analysis of West Nile virus strains isolated from the United States, Europe, and the Middle East. Virology 2002; 298: 96-105
45. Charrel R, Brault A, Gallian P, et al. Evolutionary relationship between Old World West Nile virus strains: evidence for viral gene flow between Africa, the Middle East, and Europe. Virology 2003; 315: 381-8
46. Ceccaldi PE, Lucas M, Despres P. New insights on the neuropathogenicity of West Nile virus. FEMS Microbiol Lett 2004; 223: 1-6
47. O'Leary D, Marfin AA, Montgomery SP, et al. The epidemic of West Nile virus in the United States, 2002. Vector Borne Zoonotic Dis 2004; 4: 61-70
48. Ben-Nathan D, Lustig S, Tam G, et al. Prophylactic and therapeutic efficacy of human intravenous immunoglobulin in treating West Nile virus infection in mice. J Infect Dis 2003; 188: 5-12
49. Diamond MS, Shrestha B, Marri A, et al. B cells and antibody play critical roles in the immediate defense of disseminated infection by West Nile encephalitis virus. J Virol 2003; 77: 2578-86
50. Agrawal AG, Petersen LR. Human immunoglobulin as a treatment for West Nile virus infection. J Infect Dis 2003; 188: 1-4
51. Haley M, Retter AS, Fowler D, et al. The role for intravenous immunoglobulin in the treatment of West Nile virus encephalitis. Clin Infect Dis 2003; 37: 88-90
52. Mashimo T, Lucas M, Simon-Chazottes D, et al. A nonsense mutation in the gene encoding 2′-5′-oligoadenylate synthetase/L1 isoform is associated with West Nile virus susceptibility in laboratory mice. Proc Natl Acad Sci U S A 2002; 99: 11311-6
53. Deubel V, Fiette L, Gounon P, et al. Variations in biological features of West Nile virus. Ann N Y Acad Sci 2001; 951: 195-206